FINWIRES · TerminalLIVE
FINWIRES

欧洲、中东和非洲天然气市场最新动态:受美伊协议可能即将达成的消息影响,期货价格暴跌

By

-- 周三,欧洲天然气期货价格大幅下跌,此前有迹象表明,美国和伊朗在达成最终和平协议方面取得了一些进展,该协议旨在结束持续两个多月的冲突,这场冲突造成了石油贸易史上最严重的供应冲击之一。 这一进展的消息来自Axios一篇题为《官员称,美伊两国即将就一份结束战争的单页备忘录达成一致》的文章。 该报道援引两位美国官员和另外两位知情人士的话称,白宫认为,根据拟议的单页框架,白宫已接近与伊朗达成协议,并正在等待伊朗在周五之前的回应。 消息传出后不久,荷兰TTF天然气期货价格一度下跌近9%,但随后跌幅收窄至6.5%,至每桶43.86欧元(51.55美元)。英国NBP天然气期货价格下跌6.6%,至每桶107.5便士(1.46美元)。 然而,美国总统唐纳德·特朗普周三晚些时候在社交媒体网站Truth Social上发表的一篇文章似乎暗示伊朗方面将继续抵抗。 他重申,如果双方无法达成协议,美国将诉诸武力来实现其要求,包括伊朗放弃核浓缩活动。 “假设伊朗同意履行已达成的协议(这或许是一个很大的假设),那么已经名声大噪的‘史诗级愤怒’(Epic Fury)将会结束,而高效的封锁将使霍尔木兹海峡对所有人开放,包括伊朗。如果他们不同意,轰炸就会开始,而且不幸的是,轰炸的规模和强度将比以前更大,”特朗普写道。

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL